A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: A model system for the detection of tumor markers

Journal of Proteome Research

Volumn 7, Issue 4, 2008, Pages 1542-1554

  Orazine, Christina I ^a,b   Hincapie, Marina ^a,b   Hancock, Willianr S ^a,b   Hattersley, Maureen ^a,b   Hanke, Jeff H ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Biomarker; Breast cancer; Glycoprotein; Lectin; MCF 7; Proteomics

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; INTERLEUKIN 6 RECEPTOR; LECTIN; PHOSPHATIDYLINOSITOL KINASE; PLASMA PROTEIN; PROTEIN KINASE C; TUMOR MARKER; TUMOR PROTEIN; ESTROGEN; TAMOXIFEN; TRYPSIN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MASS SPECTROMETER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY ANALYSIS; SERUM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; BLOOD; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUDE MOUSE; OVARIECTOMY; PATHOLOGY; RANDOMIZATION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALIA; MURINAE;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTROGENS; FEMALE; GLYCOPROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OVARIECTOMY; PROTEOMICS; RANDOM ALLOCATION; TAMOXIFEN; TANDEM MASS SPECTROMETRY; TRYPSIN; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45549088058     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr7008516     Document Type: Article

References (87)

1. Omenn, G. S.; States, D. J.; Adamski, M.; Blackwell, T. W.; Menon, R.; Hermjakob, H.; Apweiler, R.; Haab, B. B.; Simpson, R. J.; Eddes, J. S.; Kapp, E. A.; Moritz, R. L.; Chan, D. W.; Rai, A. J.; Admon, A.; Aebersold, R.; Eng, J.; Hancock, W. S.; Hefta, S. A.; Meyer, H.; Paik, Y. K.; Yoo, J. S.; Ping, P.; Pounds, J.; Adkins, J.; Qian, X.; Wang, R.; Wasinger, V.; Wu, C. Y.; Zhao, X.; Zeng, R.; Archakov, A.; Tsugita, A.; Beer, I.; Pandey, A.; Pisano, M.; Andrews, P.; Tammen, H.; Speicher, D. W.; Hanash, S. M. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5 (13), 3226-45.
2. Davis, M. A.; Hanash, S. High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy. Breast Cancer Res. 2006, 8 (6), 217.
3. Gronborg, M; Kristiansen, T. Z.; Iwahori, A.; Chang, R.; Reddy, R.; Sato, N.; Molina, H.; Jensen, O. N.; Hruban, R. H.; Goggins, M. G.; Maitra, A.; Pandey, A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5 (1), 157-71.
4. Khwaja, F. W.; Svoboda, P.; Reed, M.; Pohl, J.; Pyrzynska, B.; Van Meir, E. G. Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 2006, 25 (58), 7650-61.
5. Yang, Z.; Hancock, W. S. Monitoring glycosylation pattern changes of glycoproteins using multi-lectin affinity chromatography. J. Chro- matogr., A 2005, 1070 (1-2), 57-64.
6. Uu, T.; Qian, W. J.; Gritsenko, M. A.; Camp, D. G.; II; Monroe, M. E.; Moore, R. J.; Smith, R. D. Human plasma N-glycoproteome analysis by immunoamnity subtraction, hydrazide chemistry, and mass spectrometry. J. Proteome Res. 2005, 4 (6), 2070-80.
7. Zhang, H. The plasma proteome: high abundance versus low abundance. January 10-11, 2006, San Diego, CA, USA. Expert Rev. Proteomics 2006, 3 (2), 175-8.
8. Durham, M.; Regnier, F. E. Targeted glycoproteomics: serial lectin affinity chromatography in the selection of O-glycosylation sites on proteins from the human blood proteome. J. Chromatogr., A 2006, 1132 (1-2), 165-73.
9. Madera, M.; Mechref, Y.; Klouckova, I.; Novotny, M. V. Semiau-tomated high-sensitivity profiling of human blood serum glycoproteins through lectin preconcentration and multidimensional chromatography/tandem mass spectrometry. J. Proteome Res. 2006, 5 (9), 2348-63.
10. Miyamoto, S. Clinical applications of glycomic approaches for the detection of cancer and other diseases. Curr. Opin. Mol. Ther. 2006, 8 (6), 507-13.
11. Brockhausen, I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006, 7(6), 599- 604.
12. Kobata, A.; Amano, J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol. Cell Biol. 2005, 83 (4), 429-39.
13. Yang, Z.; Harris, L. E.; Palmer-Toy, D. E.; Hancock, W. S. Multilectin affinity chromatography for characterization of multiple glycol protein biomarker candidates in serum from breast cancer patients. Clin. Chem. 2006, 52 (10), 1897-905.
14. Zhou, H. J.; Liu, Y. K.; Chui, J. F.; Sun, Q. L.; Lu, W. J.; Guo, K.; Jin, H.; Wei, L. M.; Yang, P. Y. A glycoproteome database of normal human liver tissue. J. Cancer Res. Clin. Oncol. 2007, 133 (6), 679- 87.
15. Miyoshi, E.; Noda, K.; Ko, J. H.; Ekuni, A.; Kitada, T.; Uozumi, N.; Ikeda, Y.; Matsuura, N.; Sasaki, Y.; Hayashi, N.; Hori, M.; Taniguchi, N. Overexpression of aIphal-6 fucosyltransferase in hepatoma cells suppresses intrahepatic metastasis after splenic injection in athymic mice. Cancer Res. 1999, 59 (9), 2237-43.
16. Hung, K. E.; Kho, A. T.; Sarracino, D.; Richard, L. G.; Krastins, B.; Forrester, S.; Haab, B. B.; Kohane, I. S.; Kucherlapati, R. Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J. Proteome Res. 2006, 5 (8), 1866-78.
17. Juan, H. F.; Chen, J. H.; Hsu, W. T.; Huang, S. C.; Chen, S. T.; Yi- Chung, L. J.; Chang, Y. W.; Chiang, C. Y.; Wen, L. L.; Chan, D. C.; Liu, Y. C.; Chen, Y. J. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004, 4 (9), 2766-75.
18. Celis, J. E.; Gromov, P.; Cabezon, T.; Moreira, J. M.; Ambartsumian, N.; Sandelin, K.; Rank, F.; Gromova, I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 2004, 3 (4), 327-44.
19. Plavina, T.; Wakshull, E.; Hancock, W. S.; Hincapie, M. Combination of abundant protein depletion and multi-lectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J. Proteome Res. 2007, 6 (2), 662-71.
20. Cespedes, M. V.; Casanova, I.; Parreno, M.; Mangues, R. Mouse models in oncogenesis and cancer therapy. Clin. Transl. Oncol. 2006, 8 (5), 318-29.
21. Kelland, L. R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 2004, 40 (6), 827-36.
22. Simstein, R.; Burow, M.; Parker, A.; Weldon, C.; Beckman, B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Biol. Med. 2003, 228 (9), 995-1003.
23. Rose, D. P.; Connolly, J. M. Dietary fat and breast cancer metastasis by human tumor xenografts. Breast Cancer Res. Treat. 1997, 46 (2-3), 225-37.
24. Sandhu, C.; Connor, M.; Kislinger, T.; Slingerland, J.; Emili, A. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. J. Proteome Res. 2005, 4 (3), 674-89.
25. Yavelow, J.; Tuccillo, A.; Kadner, S. S.; Katz, J.; Finlay, T. H. Alpha 1-antitrypsin blocks the release of transforming growth factor- alpha from MCF-7 human breast cancer cells. Clin. Endocrinol. Metab. 1997, 82 (3), 745-52.
26. Schiemann, S.; Schwirzke, M.; Brunner, N.; Weidle, U. H. Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. Clin. Exp. Metastasis 1998, 16 (2), 129-39.
27. Malorni, L.; Cacace, G.; Cuccurullo, M.; Pocsfalvi, G.; Chambery, A.; Farina. Proteomic analysis of MCF-7 breast cancer cell line exposed to mitogenic concentration of 17beta-estradiol. Proteomics 2006, 6 (22), 5973-82.
28. Rahbar, A. M.; Fenselau, C. Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells. J. Proteome Res. 2005, 4 (6), 2148-53.
29. Chen, S. T.; Pan, T. L.; Tsai, Y. C.; Huang, C. M. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 2002, 181 (1), 95-107.
30. Hathout, Y.; Gehrmann, M. L.; Chertov, A.; Fenselau, C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett. 2004, 210 (2), 245-53.
31. Kerbel, R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2003, 2 (4), S134-9.
32. Shen, Y.; Kim, J.; Strittmatter, E. F.; Jacobs, J. M.; Camp, D. G., 2nd; Fang, R.; Tolie, N.; Moore, R. J.; Smith, R. D. Characterization of the human blood plasma proteome. Proteomics 2005, 5 (15), 4034-45.
33. Sadygov, R. G.; Cociorva, D.; Yates, J. R., III. Large-scale database searching using tandem mass spectra: looking up the answer in the back of the book. Nat. Methods 2004, 1 (3), 195-202.
34. Bernhard, O. K.; Kapp, E. A.; Simpson, R. J. Enhanced analysis of the mouse plasma proteome using cysteine-containing tryptic glycopeptides. J. Proteome Res. 2007, 6 (3), 987-95.
35. Williams, A. F.; Parekh, R. B.; Wing, D. R.; Willis, A. C.; Barclay, A. N.; Dalchau, R.; Fabre, J. W.; Dwek, R. A.; Rademacher, T. W. Comparative analysis of the N-glycans of rat, mouse and human Thy-1. Site-specific oligosaccharide patterns of neural Thy-1, a member of the immunoglobulin superfamily. Glycobiology 1993, 3 (4), 339-48.
36. Hoffman, S.; Chuong, C. M.; Edelman, G. M. Evolutionary conservation of key structures and binding functions of neural cell adhesion molecules. Proc. Natl. Acad. Set U.S.A. 1984, 81 (21), 6881-5.
37. Koibuchi, Y.; lino, Y.; Uchida, T.; Andoh, T.; Horii, Y; Nagasawa, M.; Horiguchi, J.; Maemura, M.; Takei, H.; Yokoe, T.; Morishita, Y. Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice, Oncol. Rep. 2000, 7 (1), 135-40.
38. Wolf, D. M.; lordan, V. C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast. Cancer Res. Treat. 1994, 31 (1), 117-27.
39. Goswami, S.; Sahai, E.; Wyckoff, J. B.; Cammer, M.; Cox, D.; Pixley, F. J.; Stanley, E. R.; Segall, J. E.; Condeelis, J. S. Macrophages promote the invasion of breast carcinoma cells via a colony- stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005, 65 (12), 5278-83.
40. Lee, A. V.; Jackson, J. G.; Gooch, J. L.; Hilsenbeck, S. G.; Coronado- Heinsohn, E.; Osborne, C. K.; Yee, D. Enhancement of insulinlike growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 1999, 13 (5), 787-96.
41. Jordan, V. C.; Fritz, N. F.; Gottardis, M. M. Strategies for breast cancer therapy with antiestrogens. J. Steroid Biochem. 1987, 27 (1-3), 493-8.
42. Molloy, C. A.; May, F. E.; Wesdey, B. R. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J. Biol. Chem. 2000, 275 (17), 12565-71.
43. Stuelten, C. H.; DaCosta Byfield, S.; Arany, P. R.; Karpova, T. S.; Stetler-Stevenson, W. G.; Roberts, A. B. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J. Cell Sci 2005, 118 (10), 2143-53.
44. Harkonen, P. L.; Vaananen, H. K. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann. N.Y. Acad. Sci. 2006, 1089, 218-27.
45. Hussein, M. R. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int. J. Exp. Pathol. 2006, 87 (3), 163-76.
46. Creighton, C. J.; Bromberg-White, J. L.; Misek, D. E.; Monsma, D. J.; Brichory, F.; Kuick, R.; Giordano, T. J.; Gao, W.; Omenn, G. S.; Webb, C. P.; Hanash, S. M. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol. Cancer Res. 2005, 3 (3), 119-29.
47. Yoshimura, A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006, 97 (6), 439-47.
48. Dirkx, A. E.; Oude Egbrink, M. G.; Kuijpers, M. J.; van der Niet, S. T.; Heijnen, V. V.; Bouma-ter Steege, J. C.; Wagstaff, J.; Griffioen, A. W. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003, 63 (9), 2322-9.
49. Kairouz, R.; Daly, R. J. Tyrosine kinase signaling in breast cancer: modulation of tyrosine kinase signaling in human breast cancer through altered expression of signaling intermediates. Breast Cancer Res. 2000, 2 (3), 197-202.
50. Olayioye, M. A. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001, 3 (6), 385-9.
51. Krasilnikov, M. A. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Moscow) 2000, 65 (1), 59-67.
52. Le Page, C.; Koumakpayi, I. FL; Lessard, L.; Saad, F.; Mes-Masson, A. M. Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate 2005, 65 (4), 306-15.
53. Reddy, S. A.; Lin, Y. F.; Huang, H. J.; Samanta, A. K.; Liao, W. S. The IL-1 receptor accessory protein is essential for PI 3-kinase recruitment and activation. Biochem. Biophys. Res. Commun. 2004, 316 (4), 1022-8.
54. Gu, C.; Park, S. The EphA8 receptor regulates integrin activity through pllOgamma phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol. Cell. Biol. 2001, 21 (14), 4579-97.
55. Friedmann, B. J.; Caplin, M.; Savic, B.; Shah, T.; Lord, C. J.; Ashworth, A.; Hartley, J. A.; Hochhauser, D. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol. Cancer Ther. 2006, 5 (2), 209-18.
56. Prokopcova, J.; Kleibl, Z.; Banwell, C. M.; Pohlreich, P. The role of ATM in breast cancer development. Breast Cancer Res. Treat. 2007, 104 (2), 121-8.
57. Mann, K. J.; Hepworth, M. R.; Raikwar, N. S.; Deeg, M. A.; Sevlever, D. Effect of glycosylphosphatidylinositol (GPI)-phospholipase D overexpression on GPI metabolism. Biochem. J. 2004, 378 Pt 2, 641-8.
58. Arreaza, G.; Brown, D. A. Sorting and intracellular trafficking of a glycosylphosphatidylinositol-anchored protein and two hybrid transmembrane proteins with the same ectodomain in Madin- Darby canine kidney epithelial cells. J. Biol. Chem. 1995, 270 (40), 23641-7.
59. Yeh, Y. T.; Ou-Yang, F.; Chen, I. F.; Yang, S. F.; Su, J. H.; Hou, M. F.; Yuan, S. S. Altered p-JAKl expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma. Oncol. Rep. 2007, 17(1), 35-9.
60. Muller, V.; Witzel, I.; Pantel, K.; Krenkel, S.; Luck, H. J.; Neumann, R.; Keller, T.; Dittmer, I.; Janicke, F.; Thomssen, C. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 2006, 26 (2B), 1479-87.
61. Yarden, R. I.; Wilson, M. A.; Chrysogelos, S. A. Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J. Cell Biochem. 2001, 81 (S36), 232-46.
62. Ellis, M. I.; Singer, C.; Hornby, A.; Rasmussen, A.; Cullen, K. J. Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer. Breast Cancer Res. Treat. 1994, 31 (2-3), 249-61.
63. Guddo, F.; Fontanini, G.; Reina, C.; Vignola, A. M.; Angeletti, A.; Bonsignore, G. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum. Pathol. 1999, 30 (7), 788-94.
64. Fromigue, O.; Kheddoumi, N.; Body, J. J. Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br. J. Cancer 2003, 89 (1), 178-84.
65. Olapade-Olaopa, E. O.; MacKay, E. H.; Taub, N. A.; Sandhu, D. P.; Terry, T. R.; Habib, F. K. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin. Cancer Res. 1999, 5 (3), 569-76.
66. Fiuraskova, M.; Brychtova, S.; Sedlakova, E.; Benes, P.; Zalesak, B.; Hlobilkova, A.; Tichy, M.; Kolar, Z. Molecular changes in PDEGF and bFGF in malignant melanomas in relation to the stromal microenvironment. Anticancer Res. 2005, 25 (6B), 4299- 303.
67. Hawkin, R. A.; Arends, M. J.; Ritchie, A. A.; Langdon, S.; Miller, W. R. Tamoxifen increases apoptosis but does not influence markers of proliferation in an MCF-7 xenograft model of breast cancer. Breast 2000, 9 (2), 96-106.
68. Mandlekar, S.; Kong, A. N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6 (6), 469-77.
69. Wilmes, P.; Bond, P. L. The application of two-dimensional polyacrylamide gel electrophoresis and downstream analyses to a mixed community of prokaryotic microorganisms. Environ. Microbiol. 2004, 6 (9), 911-20.
70. Sam-Yellowe, T. Y.; Florens, L.; Wang, T.; Raine, J. D.; Carucci, D. J.; Sinden, R.; Yates, I. R., III. Proteome analysis of rhoptry-enriched fractions isolated from Plasmodium.merozoites. J. Proteome Res. 2004, 3 (5), 995-1001.
71. Wang, Y.; Wu, S. L.; Hancock, W. S. Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap-Fourier transform mass spectrometry. Glycobiology 2006, 16 (6), 514-23.
72. Ren, J. M.; Rejtar, T.; Li, L.; Karger, B. L. N-Glycan structure annotation of glycopeptides using a linearized glycan structure database (GlyDB). J. Proteome Res. 2007, 6 (8), 3162-73.
73. den Hollander, P.; Kumar, R. Dynein light chain 1 contributes to cell cycle progression by increasing cyclin-dependent kinase 2 activity in estrogen-stimulated cells. Cancer Res. 2006, 66 (11), 5941-9.
74. Niculescu, F.; Rus, H. G.; Retegan, M.; Vlaicu, R. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 1992, 140 (5), 1039-43.
75. Carriero, M. V.; Del Vecchio, S.; Franco, P.; Potena, M. I.; Chiara- donna, F.; Botti, G.; Stoppelli, M. P.; Salvatore, M. Vitronectin binding to urokinase receptor in human breast cancer. Clin. Cancer Res. 1997, 3 (8), 1299-308.
76. Li, Y.; Knisely, J. M.; Lu, W.; McCormick, L. M.; Wang, J.; Henkin, J.; Schwartz, A. L.; Bu, G. Low density lipoprotein (LDL) receptor- related protein IB impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J. Biol. Chem. 2002, 277 (44), 42366-71.
77. Bourguignon, L. Y.; Zhu, H.; Zhou, B.; Diedrich, F.; Singleton, P. A.; Hung, M. C. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-pl85(HER2) and induces Racl and Ras signaling during ovarian tumor cell migration and growth. J. Biol. Chem. 2001, 276 (52), 48679-92.
78. Johnson, J.; Albarani, V.; Nguyen, M.; Goldman, M.; Willems, F.; Aksoy, E. Protein kinase Ca is involved in IRF-3 activation and type I IFN-β synthesis. J. Biol. Chem. 2007, 282 (20), 15022-32.
79. Grossoni, V. C.; Falbo, K. B.; Kazanietz, M. G.; de Kier Joffe, E. D.; Urtreger, A. J. Protein kinase C δ enhances proliferation and survival of murine mammary cells. Mol. Carcinog. 2007, 46, 381- 90.
80. Carey, I.; Williams, C. L.; Ways, D. K.; Noti, J. D. Overexpression of protein kinase C-alpha in MCF-7 breast cancer cells results in differential regulation and expression of alphavbeta3 and alphav-beta5. Int. J. Oncol. 1999, 15 (1), 127-36.
81. Mazurkiewicz, M.; Opolski, A.; Wietrzyk, J.; Radzikowski, C.; Kleinrok, Z. GABA level and GAD activity in human and mouse normal and neoplastic mammary gland. J. Exp. Clin. Cancer Res. 1999 Jun, 18 (2), 247-53.
82. Thompson, D. K.; Haddow, J. E.; Smith, D. E.; Ritchie, R. F. Elevated serum acute phase protein levels as predictors of disseminated breast cancer. Cancer 1983, 51 (11), 2100-4.
83. Zhai, Y.; Wu, R.; Schwartz, D. R.; Darrah, D.; Reed, H.; Kolligs, F. T.; Nieman, M. T.; Fearon, E. R.; Cho, K. R. Role of beta-catenin/T- cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am. J. Pathol. 2002, 160 (4), 1229-38.
84. Berquin, I. M.; Pang, B.; Dziubinski, M. L.; Scott, L. M.; Chen, Y. Q.; Nolan, G. P.; Ethier, S. P. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005, 24 (19), 3177-86.
85. van Kooij, M.; de Groot, K.; van Vugt, PL; Aten, J.; Snoek, M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics 2001, 53 (8), 656- 61.
86. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proa Natl. Acad. Sci. U.S.A. 1998, 95 (26), 15665-70.
87. Wilson, A. C.; Boutros, M.; Johnson, K. M.; Herr, W. HCF-1 amino- and carboxy-terminal subunit association through two separate sets of interaction modules: involvement of fibronectin type 3 repeats. Mol. Cell. Biol. 2000, 20 (18), 6721-30.